Morgan Stanley Reiterates GBX 5,000 Price Target for AstraZeneca plc (AZN)
Morgan Stanley set a GBX 5,000 ($65.76) price target on AstraZeneca plc (LON:AZN) in a report published on Friday. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.
Several other equities analysts have also recently weighed in on AZN. Citigroup Inc. restated a buy rating and issued a GBX 6,000 ($78.92) price objective on shares of AstraZeneca plc in a report on Thursday, July 13th. Barclays PLC set a GBX 6,300 ($82.86) target price on shares of AstraZeneca plc and gave the company a buy rating in a research note on Wednesday, September 13th. Goldman Sachs Group, Inc. (The) reiterated a sell rating and issued a GBX 3,800 ($49.98) target price on shares of AstraZeneca plc in a research note on Tuesday, October 17th. Liberum Capital reiterated a buy rating and issued a GBX 4,800 ($63.13) target price on shares of AstraZeneca plc in a research note on Tuesday, September 5th. Finally, Natixis upgraded shares of AstraZeneca plc from a neutral rating to a buy rating and raised their target price for the company from GBX 5,000 ($65.76) to GBX 5,738 ($75.47) in a research note on Wednesday, September 6th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the company. The stock has a consensus rating of Hold and an average target price of GBX 5,247.18 ($69.01).
AstraZeneca plc (LON AZN) traded up GBX 60 ($0.79) during mid-day trading on Friday, hitting GBX 4,930 ($64.84). The stock had a trading volume of 2,560,000 shares, compared to its average volume of 1,990,000. AstraZeneca plc has a one year low of GBX 3,996 ($52.56) and a one year high of GBX 5,520 ($72.60).
COPYRIGHT VIOLATION NOTICE: “Morgan Stanley Reiterates GBX 5,000 Price Target for AstraZeneca plc (AZN)” was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/morgan-stanley-reiterates-gbx-5000-price-target-for-astrazeneca-plc-azn/1701022.html.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.